What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?
Navigating new challenges of market access and reimbursement for new pharmaceuticals in today's market
Recent changes in the orphan drug market access landscape and implications for pharmaceutical developers